Aktie A3E1Z7 SURROZEN, INC.
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren

Andere Sprachen Surrozen, Inc.

Aktien

A3E1Z7

US86889P2083

SRZN

Markt geschlossen - Nasdaq
Andere Börsenplätze
 22:30:00 26.04.2024 		% 5 Tage % 1. Jan.
8.98 USD +4.30% Intraday Chart für Surrozen, Inc. -4.52% -4.47%
10.04. Surrozen, Inc. meldet Ergebnis für das am 31. Dezember 2023 endende Geschäftsjahr CI
08.04. Surrozen-Insider kaufte Aktien im Wert von $2.999.994, laut einer aktuellen SEC-Einreichung MT

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
Surrozen, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Surrozen Insider Bought Shares Worth $2,999,994, According to a Recent SEC Filing
Surrozen, Inc. announced that it has received $17.500008 million in funding from The Column Group, LLC, Ra Capital Management, Inc.
Surrozen Publishes Study in 'Respiratory Research' Demonstrating the Promise of a Wnt Mimetic Antibody in Treating Pulmonary Fibrosis
Surrozen Announces Safety, Pharmacodynamic and Liver Function Data for SZN-043
Surrozen Announces up to $192.5 Million Private Placement of Securities Priced At-the-Market Under Nasdaq Rules
Surrozen Provides Update on the Phase 1A Clinical Trial of SZN-043 in Healthy Volunteers and Patients with Cirrhosis
Surrozen, Inc. announced that it expects to receive $17.549999 million in funding
Surrozen, Inc. Appoints Charles Williams to the Concurrent Position of Chief Operating Officer
Sector Update: Health Care Stocks Softer Late Thursday Afternoon
Sector Update: Health Care Stocks Weaker Thursday Afternoon
Surrozen to Stop Inflammatory Bowel Disease Clinical Trial; Shares Fall
Surrozen Provides Corporate Update on Clinical Programs
Surrozen, Inc. Provides Corporate Update on Clinical Programs
Surrozen, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Surrozen Provides Third Quarter 2023 Financial Results
Surrozen, Inc. Expects to Initiate A Phase 1a Clinical Trials for SZN-043 and SZN-1326 in Moderate to Severe Alcoholic Hepatitis
Surrozen, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
Surrozen Provides Second Quarter 2023 Financial Results
Surrozen, Inc. Announces Management Changes
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. A3E1Z7 Aktie
  4. Nachrichten Surrozen, Inc.
  5. Andere Sprachen